UroGen Pharma Statistics
Total Valuation
UroGen Pharma has a market cap or net worth of $2.13 billion. The enterprise value is $2.22 billion.
| Market Cap | 2.13B |
| Enterprise Value | 2.22B |
Important Dates
The last earnings date was Wednesday, August 5, 2026, before market open.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
UroGen Pharma has 48.88 million shares outstanding. The number of shares has increased by 4.63% in one year.
| Current Share Class | 48.88M |
| Shares Outstanding | 48.88M |
| Shares Change (YoY) | +4.63% |
| Shares Change (QoQ) | +0.39% |
| Owned by Insiders (%) | 1.89% |
| Owned by Institutions (%) | 86.76% |
| Float | 43.41M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 29.28 |
| PS Ratio | 11.30 |
| Forward PS | 4.84 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 11.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.80
| Current Ratio | 3.80 |
| Quick Ratio | 3.18 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.11 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -18.06% |
| Return on Invested Capital (ROIC) | -85.17% |
| Return on Capital Employed (ROCE) | -34.96% |
| Weighted Average Cost of Capital (WACC) | 12.37% |
| Revenue Per Employee | $629,113 |
| Profits Per Employee | -$325,453 |
| Employee Count | 300 |
| Asset Turnover | 0.82 |
| Inventory Turnover | 1.09 |
Taxes
| Income Tax | -472,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +123.23% in the last 52 weeks. The beta is 1.57, so UroGen Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.57 |
| 52-Week Price Change | +123.23% |
| 50-Day Moving Average | 41.72 |
| 200-Day Moving Average | 27.77 |
| Relative Strength Index (RSI) | 46.15 |
| Average Volume (20 Days) | 1,020,372 |
Short Selling Information
The latest short interest is 5.12 million, so 10.48% of the outstanding shares have been sold short.
| Short Interest | 5.12M |
| Short Previous Month | 4.59M |
| Short % of Shares Out | 10.48% |
| Short % of Float | 11.79% |
| Short Ratio (days to cover) | 5.93 |
Income Statement
In the last 12 months, UroGen Pharma had revenue of $188.73 million and -$97.64 million in losses. Loss per share was -$1.97.
| Revenue | 188.73M |
| Gross Profit | 171.46M |
| Operating Income | -66.65M |
| Pretax Income | -98.11M |
| Net Income | -97.64M |
| EBITDA | -66.35M |
| EBIT | -66.65M |
| Loss Per Share | -$1.97 |
Balance Sheet
The company has $107.98 million in cash and $196.13 million in debt, with a net cash position of -$88.15 million or -$1.80 per share.
| Cash & Cash Equivalents | 107.98M |
| Total Debt | 196.13M |
| Net Cash | -88.15M |
| Net Cash Per Share | -$1.80 |
| Equity (Book Value) | -132.40M |
| Book Value Per Share | -2.71 |
| Working Capital | 173.51M |
Cash Flow
In the last 12 months, operating cash flow was -$158.92 million and capital expenditures -$218,000, giving a free cash flow of -$159.14 million.
| Operating Cash Flow | -158.92M |
| Capital Expenditures | -218,000 |
| Depreciation & Amortization | 308,000 |
| Net Borrowing | 62.78M |
| Free Cash Flow | -159.14M |
| FCF Per Share | -$3.26 |
Margins
Gross margin is 90.85%, with operating and profit margins of -35.32% and -51.73%.
| Gross Margin | 90.85% |
| Operating Margin | -35.32% |
| Pretax Margin | -51.98% |
| Profit Margin | -51.73% |
| EBITDA Margin | -35.15% |
| EBIT Margin | -35.32% |
| FCF Margin | n/a |
Dividends & Yields
UroGen Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.63% |
| Shareholder Yield | -4.63% |
| Earnings Yield | -4.58% |
| FCF Yield | -7.46% |
Analyst Forecast
The average price target for UroGen Pharma is $60.00, which is 37.55% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $60.00 |
| Price Target Difference | 37.55% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 83.74% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
UroGen Pharma has an Altman Z-Score of -3.23 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.23 |
| Piotroski F-Score | 2 |